China’s homemade oral COVID-19 drug SIM0417, or Xiannuoxin, is expected to enter the market in two weeks, said its developer.

It is estimated that the drug would be provided to tens of millions of people after its production capacity stabilizes, its developer told Securities Daily, a Chinese media outlet focusing on securities and market news.

Beijing Municipal Health Insurance Bureau on Monday announced the initial quotation of Xiannuoxin, at 750 yuan (about $111.16) per box, or for each course of treatment, containing Simnotrelvirand Ritonavir tablets whose specifications are 0.375g and 0.1g, respectively.

Xiannuoxin, co-developed by Nanjing-based Simcere Group, the Shanghai Institute of Materia Medica and the Wuhan Institute of Virology under the Chinese Academy of Sciences, is available for the treatment of mild and moderate COVID-19 patients and prevention of severe COVID-19 symptoms.

Currently, there are five orl Covid drugs granted approval to enter the Chinese market, including two imported drugs, Paxlovid and Molnupiravir, and three homegrown drugs, SIM0417, VV116, and Azvudine.

In addition, Japan-made oral COVID drug Xocova has applied to the National Medical Products Administration for entry into China’s market.